probenecid has been researched along with HIV Coinfection in 19 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first randomized controlled trial to demonstrate a high efficacy of amoxicillin-based regimens for treating syphilis in patients with HIV infection, and the non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid was not seen." | 9.69 | Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial. ( Ando, N; Aoki, T; Gatanaga, H; Hiramoto, S; Inamura, N; Kikuchi, Y; Mizushima, D; Nemoto, T; Oka, S; Omata, K; Shiojiri, D; Takano, M; Tanuma, J; Teruya, K; Uemura, H; Watanabe, K; Yanagawa, Y, 2023) |
| " In a previous report, 3 g/day amoxicillin with probenecid was shown to be effective in treating syphilis in patients with HIV; however, 7." | 8.12 | Clinical efficacy and tolerability of 1.5 g/day oral amoxicillin therapy without probenecid for the treatment of syphilis. ( Fukushima, K; Ikeuchi, K; Imamura, A; Tanaka, M; Yajima, K, 2022) |
| "This retrospective observational study included 286 HIV-infected male patients with syphilis (median age, 36 years; median CD4 count, 389 cells/µL) who were treated with oral amoxicillin 3 g plus probenecid." | 7.81 | High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. ( Aoki, T; Gatanaga, H; Kikuchi, Y; Nishijima, T; Oka, S; Tanizaki, R; Teruya, K, 2015) |
| "This is the first randomized controlled trial to demonstrate a high efficacy of amoxicillin-based regimens for treating syphilis in patients with HIV infection, and the non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid was not seen." | 5.69 | Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial. ( Ando, N; Aoki, T; Gatanaga, H; Hiramoto, S; Inamura, N; Kikuchi, Y; Mizushima, D; Nemoto, T; Oka, S; Omata, K; Shiojiri, D; Takano, M; Tanuma, J; Teruya, K; Uemura, H; Watanabe, K; Yanagawa, Y, 2023) |
| " In a previous report, 3 g/day amoxicillin with probenecid was shown to be effective in treating syphilis in patients with HIV; however, 7." | 4.12 | Clinical efficacy and tolerability of 1.5 g/day oral amoxicillin therapy without probenecid for the treatment of syphilis. ( Fukushima, K; Ikeuchi, K; Imamura, A; Tanaka, M; Yajima, K, 2022) |
| "This retrospective observational study included 286 HIV-infected male patients with syphilis (median age, 36 years; median CD4 count, 389 cells/µL) who were treated with oral amoxicillin 3 g plus probenecid." | 3.81 | High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. ( Aoki, T; Gatanaga, H; Kikuchi, Y; Nishijima, T; Oka, S; Tanizaki, R; Teruya, K, 2015) |
| " A multicenter, open-label, randomized, crossover pharmacokinetic study with four phases was undertaken at an outpatient private research center and at university research clinics." | 2.69 | Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. ( Casserella, S; Cimoch, PJ; Griffy, KG; Jung, D; Lavelle, J; Pollard, R; Tarnowski, TL; Wong, R, 1998) |
| "The current recommendations for treating early syphilis appear adequate for most patients, whether or not they have HIV infection." | 2.68 | A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. ( Augenbraun, MH; Bolan, G; Chiu, M; French, P; Hendershot, EF; Joesoef, MR; Johnson, SC; Larsen, S; Radolf, JD; Rolfs, RT; Rompalo, AM; Steen, E, 1997) |
| "Data comparing neurosyphilis treatment regimens are limited." | 1.56 | Neurosyphilis Treatment Outcomes After Intravenous Penicillin G Versus Intramuscular Procaine Penicillin Plus Oral Probenecid. ( Dunaway, SB; Marra, CM; Maxwell, CL; Sahi, SK; Tantalo, LC, 2020) |
| " Using in vitro kinetic parameters for TFV and the OAT1 and OAT3 inhibitor probenecid, a bottom-up physiologically-based pharmacokinetic model was successfully developed for the first time that accurately describes the probenecid-TFV interaction." | 1.56 | Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis. ( Desta, Z; Gufford, BT; Liu, SN, 2020) |
| "Repeat labs also showed new onset renal failure." | 1.43 | Penicillin Encephalopathy: An Unlikely Adversary in the Treatment of Neurosyphilis--Case Report and Review of the Literature. ( Covelli, V; Khanapara, DB; Naut, ER, 2016) |
| "0 mg/kg of body weight and declined biexponentially with an overall mean +/- standard deviation terminal half-life of 2." | 1.29 | Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ( Cundy, KC; Fisher, PE; Flaherty, J; Hitchcock, MJ; Jaffe, HS; Lalezari, JP; Lietman, PS; Petty, BG; Polis, MA; Wachsman, M, 1995) |
| "Regimens accepted for the treatment of neurosyphilis appear to be adequate for the treatment of ocular syphilis in HIV-1-infected patients though further long-term follow-up will be required." | 1.28 | The ocular manifestations of syphilis in the human immunodeficiency virus type 1-infected host. ( Culbertson, WW; Holland, S; McLeish, WM; Pulido, JS; Winward, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Richardson, D | 1 |
| Goldmeier, D | 1 |
| Ando, N | 1 |
| Mizushima, D | 1 |
| Omata, K | 1 |
| Nemoto, T | 1 |
| Inamura, N | 1 |
| Hiramoto, S | 1 |
| Takano, M | 1 |
| Aoki, T | 2 |
| Watanabe, K | 1 |
| Uemura, H | 1 |
| Shiojiri, D | 1 |
| Yanagawa, Y | 1 |
| Tanuma, J | 1 |
| Teruya, K | 2 |
| Kikuchi, Y | 2 |
| Gatanaga, H | 2 |
| Oka, S | 2 |
| Dunaway, SB | 1 |
| Maxwell, CL | 1 |
| Tantalo, LC | 1 |
| Sahi, SK | 1 |
| Marra, CM | 1 |
| Liu, SN | 1 |
| Desta, Z | 1 |
| Gufford, BT | 1 |
| Ikeuchi, K | 1 |
| Fukushima, K | 1 |
| Tanaka, M | 1 |
| Yajima, K | 1 |
| Imamura, A | 1 |
| Tanizaki, R | 1 |
| Nishijima, T | 1 |
| Covelli, V | 1 |
| Khanapara, DB | 1 |
| Naut, ER | 1 |
| Regis, EG | 1 |
| Barreto-de-Souza, V | 1 |
| Morgado, MG | 1 |
| Bozza, MT | 1 |
| Leng, L | 1 |
| Bucala, R | 1 |
| Bou-Habib, DC | 1 |
| Izzedine, H | 1 |
| Thibault, V | 1 |
| Valantin, MA | 1 |
| Peytavin, G | 1 |
| Schneider, L | 1 |
| Benhamou, Y | 1 |
| Bradshaw, D | 1 |
| Nwokolo, N | 1 |
| Dahl, G | 1 |
| Keane, RW | 1 |
| Speck, RR | 1 |
| Yu, XF | 1 |
| Hildreth, J | 1 |
| Flexner, C | 1 |
| Lucia, MB | 1 |
| Savarino, A | 1 |
| Straface, E | 1 |
| Golotta, C | 1 |
| Rastrelli, E | 1 |
| Matarrese, P | 1 |
| Rutella, S | 1 |
| Malorni, W | 1 |
| Cauda, R | 1 |
| Cundy, KC | 1 |
| Petty, BG | 1 |
| Flaherty, J | 1 |
| Fisher, PE | 1 |
| Polis, MA | 1 |
| Wachsman, M | 1 |
| Lietman, PS | 1 |
| Lalezari, JP | 1 |
| Hitchcock, MJ | 1 |
| Jaffe, HS | 1 |
| Sherrard, J | 1 |
| Barlow, D | 1 |
| Rolfs, RT | 1 |
| Joesoef, MR | 1 |
| Hendershot, EF | 1 |
| Rompalo, AM | 1 |
| Augenbraun, MH | 1 |
| Chiu, M | 1 |
| Bolan, G | 1 |
| Johnson, SC | 1 |
| French, P | 1 |
| Steen, E | 1 |
| Radolf, JD | 1 |
| Larsen, S | 1 |
| Cimoch, PJ | 1 |
| Lavelle, J | 1 |
| Pollard, R | 1 |
| Griffy, KG | 1 |
| Wong, R | 1 |
| Tarnowski, TL | 1 |
| Casserella, S | 1 |
| Jung, D | 1 |
| McDermott, J | 1 |
| Kennedy, J | 1 |
| Ellis-Pegler, RB | 1 |
| Thomas, MG | 1 |
| McLeish, WM | 1 |
| Pulido, JS | 1 |
| Holland, S | 1 |
| Culbertson, WW | 1 |
| Winward, K | 1 |
1 review available for probenecid and HIV Coinfection
| Article | Year |
|---|---|
Pannexin: from discovery to bedside in 11±4 years?
Topics: Adenosine Triphosphate; Animals; Cell Death; Connexins; Gap Junctions; HIV Infections; Humans; Infla | 2012 |
4 trials available for probenecid and HIV Coinfection
| Article | Year |
|---|---|
Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug-Related Side Effects and Adverse Reactions; HIV; HIV Infect | 2023 |
Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C | 2005 |
A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group.
Topics: Adult; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; | 1997 |
Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Didanosine; Drug I | 1998 |
14 other studies available for probenecid and HIV Coinfection
| Article | Year |
|---|---|
Probenecid in the treatment of neurosyphilis in men who have sex with men: a commentary.
Topics: HIV Infections; Homosexuality, Male; Humans; Male; Neurosyphilis; Probenecid; Sexual and Gender Mino | 2022 |
Neurosyphilis Treatment Outcomes After Intravenous Penicillin G Versus Intramuscular Procaine Penicillin Plus Oral Probenecid.
Topics: HIV Infections; Humans; Neurosyphilis; Penicillin G; Penicillin G Procaine; Probenecid; Treatment Ou | 2020 |
Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.
Topics: Anti-HIV Agents; Drug Interactions; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; H | 2020 |
Clinical efficacy and tolerability of 1.5 g/day oral amoxicillin therapy without probenecid for the treatment of syphilis.
Topics: Amoxicillin; Anti-Bacterial Agents; HIV Infections; Humans; Probenecid; Retrospective Studies; Syphi | 2022 |
High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Agents; CD4 Lymphocyte Count; Drug Therapy, | 2015 |
Penicillin Encephalopathy: An Unlikely Adversary in the Treatment of Neurosyphilis--Case Report and Review of the Literature.
Topics: Adjuvants, Pharmaceutic; Aged; Anti-Bacterial Agents; Brain Diseases; Female; HIV Infections; Humans | 2016 |
Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication.
Topics: ATP-Binding Cassette Transporters; Cell Line; HIV Envelope Protein gp120; HIV Infections; HIV Long T | 2010 |
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphon | 2010 |
Dizziness and rash in an HIV positive man.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Anti-Bacterial Agents; Diagnosis, Differential | 2012 |
Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cells, Cultured; | 2002 |
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infection | 1995 |
Gonorrhoea in men: clinical and diagnostic aspects.
Topics: Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Chlamydia Infections; Chlamydia trachoma | 1996 |
Pharmacokinetics of zidovudine plus probenecid.
Topics: Drug Therapy, Combination; HIV Infections; Humans; Male; Probenecid; Zidovudine | 1992 |
The ocular manifestations of syphilis in the human immunodeficiency virus type 1-infected host.
Topics: Adult; Central Nervous System Diseases; Doxycycline; Eye Diseases; Fundus Oculi; HIV Infections; HIV | 1990 |